Online inquiry

IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9170MR)

This product GTTS-WQ9170MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9170MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4666MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ12048MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ14911MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7359MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ6637MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ10244MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ14798MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ8332MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW